Results 61 to 70 of about 1,651 (123)

Kimyrsa and Orbactiv – A Tale of Two Formulations

Drug Design, Development and Therapy, 2023
Brittany T Jackson,1 David B Cluck,2 Andrés F Henao-Martínez,3 Daniel B Chastain4 1Department of Pharmacy, Mount Sinai Morningside, New York, NY, 10025, USA; 2Department of Pharmacy Practice, Bill Gatton College of Pharmacy East Tennessee State ...
Jackson BT, Cluck DB, Henao-Martínez AF, Chastain DB   +3 more
doaj  

Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections

Infection and Drug Resistance, 2015
Subhashis Mitra, Usman Saeed, Daniel H Havlichek, Gary E Stein Department of Infectious Diseases, Michigan State University, East Lansing, MI, USA Abstract: Oritavancin, a semisynthetic derivative of the glycopeptide antibiotic chloroeremomycin ...
Mitra S, Saeed U, Havlichek DH, Stein GE
doaj  

Long-Acting Antibiotics: New Opportunities Beyond Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)!

Antibiotics
Currently, two long-acting antibiotics are available: oritavancin (ORI) and dalbavancin (DBV) [...]
Emanuele Pontali, Giammarco Baiardi, Filippo Del Puente, Francesca Mattioli   +3 more
doaj   +1 more source

The role of ArlRS in regulating oxacillin susceptibility in methicillin-resistant Staphylococcus aureus indicates it is a potential target for antimicrobial resistance breakers

Emerging Microbes and Infections, 2019
Methicillin-resistant Staphylococcus aureus (MRSA), also known as oxacillin-resistant S. aureus, is a leading cause of community and hospital associated infections globally.
Jinna Bai, Xiaoyi Zhu, Keqing Zhao, Yingjie Yan, Tao Xu, Jiaxue Wang, Jinxing Zheng, Wei Huang, Le Shi, Yongpeng Shang, Zhihui Lv, Xiaofei Wang, Yang Wu, Di Qu   +13 more
doaj   +1 more source

New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides

Pathogens
Long-acting lipoglycopeptides (LGPs), such as dalbavancin and oritavancin, are semisynthetic antibiotics known for their strong effectiveness against a wide array of Gram-positive bacteria. This includes Staphylococcus aureus, both methicillin-sensitive (
Valentina Siciliano, Flavio Sangiorgi, Pierluigi Del Vecchio, Layla Vahedi, Maya Manuela Gross, Angela Saviano, Veronica Ojetti   +6 more
doaj   +1 more source

Rational construction of a high-quality and high-efficiency biosynthetic system and fermentation optimization for A82846B based on combinatorial strategies in Amycolatopsis orientalis

Microbial Cell Factories
Background Oritavancin is a new generation of semi-synthetic glycopeptide antibiotics against Gram-positive bacteria, which served as the first and only antibiotic with a single-dose therapeutic regimen to treat ABSSSI. A naturally occurring glycopeptide
Xinyi Zhao, Chenyang Zhu, Wenli Gao, Huang Xie, Zhongyuan Lyu, Qingwei Zhao, Yongquan Li   +6 more
doaj   +1 more source

Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring. [PDF]

JAC Antimicrob Resist
Giuliano S, Martini L, Merelli M, Turicchi G, Angelini J, Ferin S, D'avolio A, Gaibani P, Bongiovanni M, Tascini C.   +9 more
europepmc   +1 more source

Correction: Alarcia-Lacalle et al. Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study. <i>Pharmaceutics</i> 2026, <i>18</i>, 628. [PDF]

Pharmaceutics
Alarcia-Lacalle A, Morán-Rodríguez MÁ, Morata L, Isla A, Canut-Blasco A, Rodríguez-Gascón A.   +5 more
europepmc   +1 more source

Optimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs. [PDF]

Antibiotics (Basel)
Worden J, Baumeister T, Eaton E.
europepmc   +1 more source

Off-label use of oritavancin: a case series on clinical effectiveness, bed-day savings and cost benefits. [PDF]

JAC Antimicrob Resist
Patel A, Walden A, Iyer S, Okoibhole A.
europepmc   +1 more source